Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, a Fully Human Anti-TNFalpha Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms GO-RAISE
- Sponsors Centocor
- 01 Dec 2023 Results of post hoc pooled analysis from GO-BEFORE, GO-AFTER, and GO-FORWARD, GO-REVEAL and GO-RAISE assessing Long-term golimumab persistence, published in the Clinical Rheumatology
- 04 Jun 2022 Results assessing probability of GLM treatment retention over a 5-year period in adult patients with immune-mediated rheumatic diseases, by indication and line of therapy, using pooled data from five Phase III trials (GO-BEFORE, GO-AFTER and GO-FORWARD 3,8 ), PsA (GO-REVEAL), and AS (GO-RAISE)) presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 05 Jun 2021 Results assessing effect of GLM on HRQoL, back pain, and sleep disturbances in phase-3 studies (NCT00265083 - GO RAISE and NCT01248793) in Asian patients with ankylosing spondylitis, presented at the 22nd Annual Congress of the European League Against Rheumatism.